Validated HPLC method for determination of carboxylic acid metabolite of clopidogrel in human plasma and its application to a pharmacokinetic study

Biomedical Chromatography

Volumn 20, Issue 12, 2006, Pages 1309-1314

  Souri, Effat ^a   Jalalizadeh, Hassan ^a   Kebriaee Zadeh, Abbas ^a   Shekarchi, Maral ^a   Dalvandi, Afshin ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antiplatelet; Carboxylic acid metabolite; Clopidogrel; Reversed phase chromatography

Indexed keywords

BIOMOLECULES; CHLORINE COMPOUNDS; METABOLITES; PHARMACOKINETICS; PLASMA (HUMAN);

ACID METABOLITES; ANTIPLATELET; CARBOXYLIC ACID METABOLITE; CLOPIDOGREL; HPLC METHOD; HUMAN PLASMAS; ITS APPLICATIONS; PHARMACOKINETIC STUDIES; REVERSED PHASE CHROMATOGRAPHY; SIMPLE++;

CARBOXYLIC ACIDS;

CARBOXYLIC ACID; CHLOROFORM; CLOPIDOGREL; DRUG METABOLITE; TICLOPIDINE;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; FLOW RATE; HUMAN; HUMAN EXPERIMENT; LIQUID LIQUID EXTRACTION; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PH; REPRODUCIBILITY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY ANALYSIS; SEPARATION TECHNIQUE; SINGLE DRUG DOSE; STRUCTURE ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRAVIOLET RADIATION; VALIDATION PROCESS;

EID: 33846189269     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.697     Document Type: Article

References (10)

1. Caplain H, Donat F, Gaud C and Necciari J. Pharmacokinetics of clopidogrel. Seminars in Thrombosis and Hemostasis 1999; 25: 25.
2. Clarke TA and Waskell LA. The methabolism clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metabolism and Disposition 2003; 31(1): 53.
3. Herbert JM, Frehel D, Vallee E, Kieffer G, Gouy D, Berger Y, Necciati J, Defreyn G and Maffrand IP. Antiplatelet drugs in ischemic stroke prevention: from monotherapy to combined treatment. Cardiovascular Drug Reviews 1993; 11: 180.
4. Jarvis B and Simpson K. Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs 2000; 60(2): 347.
5. Ksycinska H, Rudzki P and Bukowska-Kiliszek M. Determination of clopidogrel metabolite (SR26334) in human by LC-MS. Journal of Pharmaceutical and Biomedical Analysis 2006; 41(2): 533.
6. Lenz T and Wilson A. Cilinical pharmacokinetics or antiplatelet agents used in the secondary prevention of stroke. Clinical Pharmacokinetics 2003; 4(10): 900.
7. Moshfegh K, Redondo M, Julmy F, Wuillemin WA, Gebauer MU, Haeberli A and Meyer BJ. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. Journal of American College of Cardiology 2000; 36(3): 699.
8. Pereillo JM, Maftouh M, Andrieu A, Uzabiaga MF, Fedeli O, Savi P, Pascal M, Herbert JM, Maffrand JP and Picard C. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metabolism and Disposition 2002; 30(11): 1288.
9. Reist M, Roy-De Vos M, Montseny JP, Mayer JM, Carrupt PA, Berger Y and Testa B. Very slow chiral inversion of clopidogrel in rats: a pharmacokinetics and mechanistic investigation. Drug Metabolism and Disposition 2000; 28(12): 1405.
10. Singh SS, Sharma K, Barot D, Mohan PR and Lohray VB. Estimation of carboxylic acid metabolite of clopidogrel in Wister rat plasma by HPLC and its application to a pharmacokinetic study. Journal of Chromatography B 2005; 821: 173.